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Edited by Dr. Beat ImhofAbstract Leukemia inhibitory factor (LIF) is expressed in the
hypothalamic-pituitary adrenal (HPA) axis and stimulates pitu-
itary POMC transcription. The role of LIF receptor signaling in
HPA axis development was examined. Lifr / and Lifr +/+ fe-
tuses were obtained by Cesarean section on E18.5. Despite a 3-
fold induction of hypothalamic CRH mRNA, pituitary POMC
mRNA and RU486-induced ACTH levels were decreased in Lifr
/ mice. High CRH may be caused by increased central TNFa
and IL-6 expression. Lifr / mice demonstrate elevated pitui-
tary glucocorticoid (GR) and mineralocorticoid (MR) receptor
mRNA and protein levels, indicating the importance of LIF sig-
naling for HPA axis development.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cytokines are expressed in the brain and the hypothalamic-
pituitary adrenal (HPA) axis and show rapid upregulation in
response to injury and inﬂammation [1,2]. Almost all proin-
ﬂammatory cytokines stimulate the HPA axis at the hypotha-
lamic level through CRH induction, and at the level of the
pituitary corticotrophs with subsequent increase of POMC
expression and circulating ACTH [1–4].
Recent studies underscore the role of cytokines in the HPA
early development. Administration of IL-1b at birth results in
permanent HPA axis alteration [5]. Animals undergoing neo-
natal exposure to endotoxin, which is accompanied by massive
cytokine release as adults, have decreased glucocorticoid (GR)
receptor binding and decreased negative feedback regulation
of stress responses [6]. Overexpression of pituitary-directed
leukemia inhibitory factor (LIF) causes Cushingoid features
and incomplete dexamethasone suppression of ACTH [7].
The gp130 cytokines (LIF, IL-6, IL-11, OSM, CT-1, CNTF
and CLF/CLC) have overlapping functions due to the com-
mon requirement for trans-membrane gp130 to initiate the
intracellular signaling cascade [8]. LIF signaling occurs by het-
erodimerization of the low aﬃnity LIF receptor and gp130*Corresponding author. Fax: +1 310 423 0221.
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rodent hypothalamus [9] and in human and rodent pituitary
[4]. Pituitary POMC gene expression is regulated by CRH,
and LIF acts in synergy with CRH to induce POMC transcrip-
tion [4].
Disruption of the LIFR results in perinatal lethality with
multiple defects reminiscent of glucocorticoid excess, possibly
at the level of glucocorticosteroid receptors [10–12]. The goal
of this study was to examine the eﬀects of LIF signaling deﬁ-
ciency on the developing HPA axis.2. Materials and methods
2.1. Animals
The mice used in this study were previously described [11]. The line
has been bred back to C57BL/6 for over ﬁve generations. All work was
carried out following the Institutional Animal Care and Use Commit-
tee guidelines. Lifr +/ females were mated to Lifr +/ males and the
day of plug (E0.5) recorded. On embryonic day 18.5 (E18.5), fetuses
were derived by Cesarean section and genotyped by PCR [11]. In some
instances, late gestation mothers were exposed to glucocorticoid recep-
tor antagonist RU486 on E16.5 and 17.5 as previously described [12].
Brieﬂy, RU486 (National Hormone and Peptide Program) was dis-
solved to 20 mg/ml in ethanol, and administered as subcutaneous injec-
tion (2.5 lg/mouse in 0.1 ml peanut oil).2.2. Real time PCR
Real time PCR was performed for IL-6, IL-1b, POMC and 18S as
described [13]. In addition, the following speciﬁc primers were used –
GR forward: GGAAGTTAATATTTGCCAATGGAC, GR reverse:
CGCAGAAACCTTGACTGTAGC; MR forward: GTGTCTC-
CGGGTAACTCTGC, MR reverse: TGGTAATTATGAATTGTAC-
CAAA; CRH forward: GCATCCTGAGAGAAGTCCCTCTG, CRH
reverse: GCCCTGGCCATTTCCAAGAC. Samples were run in qua-
druplicate. The relative quantiﬁcation of each gene in the experimental
samples was determined from the corresponding standard curve and
normalized to 18S. mRNA levels are presented as arbitrary units rela-
tive to control, which was taken as one.
2.3. Immunohistochemistry
E18.5 fetuses were ﬁxed in 4% paraformaldehyde in PBS for paraﬃn
sectioning. Paraﬃn blocks were cut in 5–6 lm sections and stained
with hematoxylin and eosin (H&E) or antibodies to ACTH (Chemicon
International) or CRHR1 (Santa Cruz Biotechnology). Antibody
binding was visualized using the Universal Quick Kit with NovaRed
(Vector). Only within litter mice were compared.
2.4. Western blot analysis
Pituitaries were processed according to manufacturers instruction
(Immunoprecipitation Kit, Roche Diagnostics). Proteins were sepa-
rated by SDS–PAGE, electroblotted onto Millipore membranes (Mil-
lipore), and incubated with anti-GR (Aﬃnity Bioreagents) or anti-MRblished by Elsevier B.V. All rights reserved.
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sponding secondary antibodies. Immunoreactive bands were detected
by the horseradish peroxidase based ECL immunodetection system
(GE Healthcare).2.5. Statistical analysis
Data were analyzed using ANOVA followed by the non-parametric
Mann–Whitney test or Students t test. All data are presented as
means ± S.E.M. A probability of P < 0.05 was considered signiﬁcant.3. Results
3.1. CRH mRNA levels are increased and POMC mRNA levels
are reduced in Lifr / fetuses
Quantitative real time PCR measurements indicated that
CRHmRNA levels were elevated 3-fold in E18.5 Lifr/ pups
as compared to wt littermates (P < 0.05, Fig. 1A). Despite high
CRH expression, Lifr / animals had a 30% decrease in pitu-
itary POMC mRNA levels (P < 0.01, Fig. 1A).
Since pituitary POMC is processed to ACTH, it was viewed
by immunolabeling. The diﬀerence between untreated wt and
Lifr / fetuses was subtle (Fig. 1C). RU486 is a GR antago-
nist known to increase ACTH synthesis [14]. Timed pregnant
dams were treated with RU486 for two consecutive days
(E16.5, 17.5) in late gestation. Part of this study has been pub-
lished previously (Ware 2003, licensee BioMed Central Ltd.,
http://www.RBEj.com/content/1/1/43), where it was reported
that the pups of both genotypes exposed to RU486 in utero
were able to increase ACTH expression relative to untreated
fetuses. Here we re-labeled additional slides for ACTH, and
RU486-exposed fetuses were re-analyzed for pituitary ACTH
induction relative to genotype. The subtle reduction of pitui-
tary ACTH in untreated Lifr / animals became notably
more pronounced in response to RU486 (Fig. 1D and E).
Thus, RU486-induced ACTH levels appeared lower in LIFR
null mice than in wt siblings. The diﬀerences between geno-
types cannot be attributed to anatomical changes, as H&E
staining shows normal pituitary structure in Lifr / pups
(Fig. 1B).
Lifr / pituitaries also showed increased expression of
CRH receptor I (CRHRI) protein (Fig. 1F).Fig. 1. (A) Hypothalamic CRH and pituitary POMC mRNA levels
measured by real time PCR and expressed in arbitrary units. Values
are means ± S.E.M. of three or four replicate measurements for each
experimental group (n = 8–10 animals per group), *P < 0.05;
**P < 0.01. (B) H&E staining of pituitaries. (C–E) Immunolabeling
of the anterior pituitary for ACTH. (C) Pituitaries from animals that
received no intervention during gestation. (D, E) Pituitaries from
animals that were exposed during late gestation to RU486. ACTH-
positive corticotrophs are red. (F) Immunolabeling of the anterior
pituitary for CRHRI, from animals with no intervention. The size bar
represents 25 lm in (B–D) and 12.5 lm in (E) and 10 lm in (F).3.2. Altered cytokine proﬁle of Lifr / fetuses
Central cytokines can be potent stimulators of HPA func-
tion [2–4,15,16], therefore cytokine expression was assessed in
the brain and pituitary, and also in liver (Fig. 2). IL-6 expres-
sion was elevated 1.8-fold in Lifr / brain (P < 0.01) and
pituitary (P < 0.05) relative to wt littermates. Brain IL-1b
mRNA became detectable in Lifr / mice, while in wt lit-
termates it was below detection. TNFa mRNA levels were
3-fold higher in Lifr / brain as compared to the wt litter-
mates (P < 0.001). Due to disrupted LIF signaling, LIF was
induced 10-fold in brain (P < 0.05) and 1.8-fold in pituitary
(P < 0.001) of Lifr / mice. No diﬀerences in cytokine
expression were observed between Lifr / and wt animals
in liver.
3.3. Pituitary glucocorticoid and mineralocorticoid receptor
expression is induced in Lifr / fetuses
The pituitary is the most important site for negative feed-
back regulation of the HPA axis [17,18]; therefore, pituitaryGR and MR expression were analyzed. GR mRNA levels were
induced 3-fold (P < 0.01) and MR mRNA levels were elevated
2.5-fold (P < 0.05) in Lifr / as compared to wt animals
(Fig. 3A). In concordance, in Lifr / pituitaries, protein lev-
els for both GR and MR were also elevated (Fig. 3B).
Fig. 2. IL-6, IL-1b, TNFa and LIF mRNA levels in brain, pituitary,
and liver measured by real time PCR and expressed in arbitrary units.
Values are means ± S.E.M. of either three or four replicate measure-
ments for each experimental group (n = 8–10 animals per group).
*P < 0.05, **P < 0.01 and ***P < 0.001.
Fig. 3. (A) Pituitary GR and MR mRNA levels measured by real time
PCR and expressed in arbitrary units. Values are means ± S.E.M. of
three or four replicate measurements for each experimental group
(n = 8–10 animals per group). *P < 0.05, **P < 0.01. (B) Pituitary GR
and MR protein levels assessed by Western blot analysis (4 pituitaries
per sample).
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Several secretagogues stimulate pituitary POMC expression,
the most prominent of which is CRH. Proinﬂammatory cyto-
kines, such as IL-1b, IL-6 and TNFa, are also proven strongactivators of the HPA axis, triggering hypothalamic CRH or
directly aﬀecting pituitary POMC expression and ACTH re-
lease [4,15,16]. Lifr / pups demonstrate increased brain
and pituitary levels of both TNFa and IL-6 mRNA relative
to wt littermates, while brain IL-1b expression becomes detect-
able in Lifr / animals. Thus, it is reasonable to suspect
expression of central proinﬂammatory cytokines induced by
LIFR ablation to be at least partially responsible for the hypo-
thalamic CRH increase in mice.
Importantly, LIF receptor ablation results in an induction of
brain and pituitary but not liver cytokine expression, indicat-
ing that an increase in central cytokines in animals lacking
LIFR is not the outcome of a general inﬂammatory process.
This is in agreement with our earlier observation showing that
cytokines can be induced centrally to compensate for the im-
paired HPA axis function [13].
POMC is processed by proconvertase 1( PC-1) to a num-
ber of hormones, including b-endorphin, a-melanocyte stim-
ulating hormone and ACTH. Both IL-6 and LIF can
increase PC-1 activity [19]. The fact that Lifr / mice only
slightly diﬀer from wt animals in baseline ACTH content
may indicate that the increased central IL-6 expression ob-
served in these animals is suﬃcient for baseline ACTH pro-
cessing. However, when pregnant mothers are injected with
the GR antagonist, RU486, which stimulates POMC expres-
sion and ACTH release in pups [14], the induction of ACTH
appears lower in Lifr / mice. Thus, despite substantially
increased hypothalamic CRH mRNA and pituitary CRHRI
levels, and brain and pituitary proinﬂammatory cytokine
4468 C.B. Ware et al. / FEBS Letters 579 (2005) 4465–4469expression, E18.5 Lifr / pups demonstrate signiﬁcantly
lower pituitary POMC and RU486-induced ACTH levels
as compared to wt controls. These results strongly suggest
that LIF receptor ablation leads to decreased corticotrophs
sensitivity to stimulation and underscore the importance of
LIF signaling for the maintenance of POMC during embry-
onic development. Our ﬁnding that fetal pituitary primary
cells from Lifr / mice produce less ACTH in response
to CRH treatment (data not shown) further support this
conclusion. These results are also supported by earlier obser-
vations showing lower baseline and inﬂammatory-induced
POMC- and ACTH responses in LIF knockout animals [20].
Glucocorticoids modulate their eﬀects on target tissues via
mineralocorticoid and glucocorticoid receptors [21]. GR and
MR are critical for normal brain formation, for the activa-
tion of the fetal HPA axis and the initiation of parturition
and organ maturation [21–23]. In rodents, the HPA axis is
particularly susceptible to early life programming and
changes in receptor expression during embryonic develop-
ment can permanently alter HPA axis function [22,23].
Increased GR and MR levels in the Lifr / pituitary
(2.5-fold for both) while circulating corticosterone levels
are equivalent to those experienced by wt littermates [12]
indicates that LIFR ablation aﬀects GR and MR program-
ming.
Many species experience a maternal surge in plasma cor-
ticosterone during late gestation [24]. It appears that Lifr
/ fetuses are particularly vulnerable to high maternal
glucocorticoid levels. Liver glycogen storage is strikingly ele-
vated in Lifr / animals, which also suﬀer osteopenia [11],
neurodegeneration [10,11] and muscle wasting [12]. All are
symptoms of glucocorticoid excess presumably implemented
through elevated MR and GR levels. Such excess response
to steroids is likely to be incompatible with life ex utero
[12]. High levels of GR and MR in Lifr / mice may also
lead to increased feedback inhibition and hence additional
dampening of pituitary POMC [18]. However, if this is the
case, by blocking glucocorticoid receptors, RU486 would
be expected to induce higher ACTH levels in knockout than
in wt animals. Yet, RU486-stimulated ACTH response is
lower in Lifr / mice, implicating that decreased POMC
expression in these animals is not a result of stronger feed-
back inhibition, but more likely is a direct eﬀect of LIF sig-
naling deﬁciency during development.
Proinﬂammatory cytokines often provoke tissue-speciﬁc de-
creased sensitivity to the eﬀects of glucocorticoids [25,26].
Here, we describe that LIF signaling ablation is associated
with increased sensitivity to glucocorticoids during embryonic
development.
In summary, LIF signaling is required for appropriate
POMC and MR and GR expression in the developing hypo-
thalamic-pituitary axis. Because the LIFR subunit is utilized
by several gp130 cytokines, we cannot exclude the cumula-
tive eﬀect of their signaling deﬁciency on alterations
observed in the HPA axis. However, taken together with
previous ﬁnding showing an impaired HPA axis stress re-
sponse in LIF knockout animals [4,19] and altered HPA axis
feedback regulation in mice with pituitary-directed LIF over-
expression [7], these results underscore a critical role of LIF
for HPA axis development and function and demonstrate a
new, non-inﬂammatory role for cytokines in early HPA axis
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